Photodynamic therapy is a promising approach for cancer treatment that relies on the
administration of a photosensitizer followed by tumor illumination. The generated oxidative …

The immunogenicity of cancer cells is an emerging determinant of anti‐cancer
immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell‐based …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

Dendritic cells (DCs) are a unique class of immune cells that act as a bridge between innate
and adaptive immunity. The discovery of DCs by Cohen and Steinman in 1973 laid the …

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based
vaccination could integrate the current standard of care for the treatment of a large variety of …

The expression “immunogenic cell death”(ICD) refers to a functionally unique form of cell
death that facilitates (instead of suppressing) a T cell-dependent immune response specific …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Dendritic cells (DCs) are key regulators of immune responses that operate at the interface
between innate and adaptive immunity, and defects in DC functions contribute to the …

Breast cancer is one of the leading causes of death in women. With improvements in early-
stage diagnosis and targeted therapies, there has been an improvement in the overall …